Crescita Therapeutics (TSX:CTX) Current Accrued Expense: C$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:CTX Crescita Therapeutics Inc TSX:CTX
20 GF Score
Price C$0.79
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics Current Accrued Expense?

Crescita Therapeutics TSX:CTX 20 Current Accrued Expense is C$0.00 Mil as of Mar. 2026. GuruFocus rates TSX:CTX with a GF Score™ of 20/100. The stock has 5 warning signs investors should review.

Crescita Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was C$0.00 Mil.

Crescita Therapeutics Current Accrued Expense Related Terms

Crescita Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Crescita Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescita Therapeutics Current Accrued Expense Chart

Crescita Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Crescita Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSX:CTX
20GF Score
Crescita Therapeutics Inc TSX:CTX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescita Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of C$0.00 Mil mean?
Crescita Therapeutics (TSX:CTX) has a Current Accrued Expense of C$0.00 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Crescita Therapeutics and its competitors.
Is Crescita Therapeutics' Current Accrued Expense too high?
Crescita Therapeutics' current Current Accrued Expense is C$0.00 Mil. Overall, Crescita Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' Current Accrued Expense compare to ZTS?
Crescita Therapeutics' Current Accrued Expense of C$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current Current Accrued Expense is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Crescita Therapeutics (TSX:CTX) has a current Current Accrued Expense of C$0.00 Mil. The current Current Accrued Expense is C$0.00 Mil. Crescita Therapeutics' overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Crescita Therapeutics (TSX:CTX), the current Current Accrued Expense is C$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
20GF Score

Get the complete analysis for TSX:CTX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.79
Price